Grace Therapeutics, Inc.
Grace Therapeutics, Inc. (GRCE): 4 pipeline candidates · ~25 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
25.3 months
D/E 0.06 · 9% dilution
Lead: Phase 3
4 candidates
N/A
N/A
A transparent, data-derived signal for Grace Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$34.2M
Cash
$18.7M
Quarterly Burn
$2.2M
Runway
25.3 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| gtx-101 | Preclinical |
| gtx-102 | Preclinical |
| gtx-104 | Phase 3 |
| gtx-104 for formal review | — |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
32
Total value held
$11.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 803,312 | $3.7M |
| bank of america corp /de/ | 494,723 | $2.3M |
| renaissance technologies llc | 243,910 | $1.1M |
| jane street group, llc | 167,097 | $774K |
| susquehanna international group, llp | 112,800 | $522K |
| citadel advisors llc | 98,742 | $457K |
| marshall wace, llp | 91,416 | $423K |
| connective capital management, llc | 84,549 | $391K |
| quadrature capital ltd | 66,822 | $309K |
| xtx topco ltd | 63,094 | $292K |
Showing top 10 of 32 institutional holders of Grace Therapeutics, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Grace Therapeutics, Inc.'s pipeline?
Grace Therapeutics, Inc. (GRCE) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Grace Therapeutics, Inc.'s lead drug candidate?
Grace Therapeutics, Inc.'s most advanced tracked candidate is gtx-101 (Preclinical) for Postherpetic Neuralgia (PHN).
What is Grace Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Grace Therapeutics, Inc. has approximately 25.3 months of cash runway.
What is Grace Therapeutics, Inc.'s market capitalization?
Grace Therapeutics, Inc.'s market capitalization is approximately $34.2M.
Who is the CEO of Grace Therapeutics, Inc.?
Mr. Prashant Kohli is the chief executive officer of Grace Therapeutics, Inc. (GRCE).
Get the full picture on Grace Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.